Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04818866 · ClinicalTrials.gov registry record
International Study of Inflammation in COVID-19
A clinical trial, sponsored by University of Michigan.
- Completed
- Registry status
- 4,463
- Enrollment target
NCT04818866: Completed study, sponsored by University of Michigan.
NCT04818866 is a clinical trial that has completed, run by University of Michigan. The registered enrollment target is 4,463 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04818866 has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- 4,463 participants
- Enrollment target
Study Summary
This is a prospective multi-center observational study which purpose is to evaluate the ability of blood-based inflammatory markers to risk-stratify patients hospitalized for Covid-19. Blood-based biomarkers examined include: soluble urokinase plasminogen activator receptor (suPAR), C-reactive protein (CRP), procalcitonin, D-dimer, ferritin, lactate dehydrogenase and interleukin-6.
Primary Outcome
Composite outcome of death, need for mechanical ventilation, need for renal replacement therapy
Interventions
- DIAGNOSTIC_TEST SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,463 participants |
| Start Date | 2020-02-01 |
| Est. Completion | 2022-12-01 |
What the finished NCT04818866 record still lists
NCT04818866 is an observational study that tracks outcomes without assigning an intervention. Its 4,463 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase is the first listed.
NCT04818866 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04818866 about?
NCT04818866 is a clinical study titled "International Study of Inflammation in COVID-19". This is a prospective multi-center observational study which purpose is to evaluate the ability of blood-based inflammatory markers to risk-stratify patients hospitalized for Covid-19. Blood-based biomarkers examined include: soluble urokinase plasminogen activator receptor (suPAR), C-reactive prote...
What is the current status of trial NCT04818866?
This trial is currently completed. The enrollment target is 4,463 participants. The study started on 2020-02-01. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT04818866?
The interventions under investigation include: SuPAR, C-reactive protein, Ferritin, D-Dimer, Procalcitonin, Interleukin-6, Lactate Dehydrogenase (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04818866?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06252753 · 4,490 participants
Observational Study Protocol: LIVER-R
- NCT06533111 · 4,500 participants · NA
Improving Surgical Patient Outcomes Through Implementation of a SemiStructured Intraoperative Anesthesia Handoff Tool
- NCT06588452 · 4,500 participants
Manual Versus AI-Assisted Clinical Trial Screening Using Large-Language Models
- NCT07165028 · 4,500 participants · Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI